beizray
(Docetaxel)Zhuhai Beihai Biotech Co., Ltd.
Usage: BEIZRAY, in combination with cisplatin and fluorouracil, is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
3 results
erbitux
(cetuximab)ImClone LLCUsage: ERBITUX is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN), recurrent or metastatic SCCHN, K-Ras wild-type metastatic colorectal cancer (mCRC), and BRAF V600E mutation-positive mCRC in combination with specific therapies. It is not for Ras-mutant cancers.opdivo
(nivolumab)E.R. Squibb & Sons, L.L.C.Usage: OPDIVO is indicated for the treatment of various cancers, including unresectable/metastatic melanoma, neoadjuvant and adjuvant non-small cell lung cancer, metastatic non-small cell lung cancer, malignant pleural mesothelioma, advanced renal cell carcinoma, classical Hodgkin lymphoma, and others. It is used in different combinations and settings based on the cancer type.